#6 - Cellectis (NASDAQ:CLLS)
For even more risk-tolerant investors, Cellectis (NASDAQ:CLLS) is a biotech stock that is currently trading under $10. Like Editas Medicine, Cellectis is in the field of gene editing. However, whereas Editas uses the CRISPR/Cas9 platform, Cellectis uses a gene-editing technology called TALEN.
The company also specializes in oncology treatments and has six candidates in its pipeline including three wholly-controlled candidates. That being said, CLLS stock is down 68% in 2021 and it’s unclear at this time whether the stock has found a floor.
However, analysts remain very bullish on CLLS stock with a consensus price target of $23.25 which would be a gain of 170% from its current price. And the stock does appear to be gaining interest from institutional investors, which is usually a signal that the stock could be ready to rise.
About Cellectis
Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed or refractory for non-hodgkin lymphoma (NHL); and ALLO-715 for the treatment of multiple myeloma.
Read More - Current Price
- $1.64
- Consensus Rating
- Buy
- Ratings Breakdown
- 3 Buy Ratings, 0 Hold Ratings, 0 Sell Ratings.
- Consensus Price Target
- $7.00 (326.8% Upside)
